Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Net Income Loss of -$6.08 million for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -69.5% in Net Income Loss from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$368.8 thousand | Q3 2013: -$313.1 thousand | Q1 2014: -$928.8 thousand | Q2 2014: -$741.3 thousand | Q3 2014: -$501.4 thousand | Q1 2015: -$957.9 thousand | Q2 2015: -$500.7 thousand | Q3 2015: -$779.7 thousand | Q1 2016: -$416.5 thousand | Q2 2016: -$555.0 thousand | Q3 2016: -$646.9 thousand | Q1 2017: -$620.6 thousand | Q2 2017: -$292.8 thousand | Q3 2017: -$462.4 thousand | Q1 2018: -$379.2 thousand | Q2 2018: -$371.4 thousand | Q3 2018: -$1.03 million | Q1 2019: -$428.7 thousand | Q2 2019: -$610.5 thousand | Q3 2019: -$1.08 million | Q1 2020: -$383.2 thousand | Q2 2020: -$373.1 thousand | Q3 2020: -$1.60 million | Q1 2021: -$1.73 million | Q2 2021: -$1.73 million | Q3 2021: -$1.24 million | Q1 2022: -$1.66 million | Q2 2022: -$1.55 million | Q3 2022: -$1.48 million | Q1 2023: -$1.37 million | Q2 2023: -$1.67 million | Q3 2023: -$1.02 million | Q1 2024: -$971.3 thousand | Q2 2024: -$1.01 million | Q3 2024: -$986.0 thousand | Q1 2025: -$709.6 thousand | Q2 2025: -$775.7 thousand | Q3 2025: -$1.98 million.
- Over the full 20 years of available data (2006 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Net Income Loss has declined by 981.4%.
- Historical annual values: Fiscal year 2025: -$6.08 million | Fiscal year 2024: -$3.59 million | Fiscal year 2023: -$5.09 million | Fiscal year 2022: -$6.31 million | Fiscal year 2021: -$6.73 million | Fiscal year 2020: -$3.26 million | Fiscal year 2019: -$2.44 million | Fiscal year 2018: -$2.13 million | Fiscal year 2017: -$1.81 million | Fiscal year 2016: -$2.13 million | Fiscal year 2015: -$2.85 million | Fiscal year 2014: -$2.77 million | Fiscal year 2013: -$1.37 million | Fiscal year 2012: -$3.58 million | Fiscal year 2011: -$2.07 million | Fiscal year 2010: -$880.3 thousand | Fiscal year 2009: -$1.55 million | Fiscal year 2008: -$1.27 million | Fiscal year 2007: -$1.65 million | Fiscal year 2006: -$562.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: